Paper Review Records
All Paper Review Records
5 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
74
days
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 study
Authors
Ying Fan; Quchang Ouyang; Yongmei Yin; Lihua Song; Xiaojia Wang; Wei Li; Man Li; Xi Yan; Shusen Wang; Tao Sun; Yuee Teng; Xianjun Tang; Zhongsheng Tong; Zhengkui Sun; Junyou Ge; Xiaoping Jin; Yina Diao; Gesha Liu; Binghe XuShow moreShow less
Affiliations
1. https://ror.org/02drdmm93grid.506261.60000 0001 0706 7839Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing, China; 2. https://ror.org/025020z88grid.410622.30000 0004 1758 2377Hunan Cancer Hospital,Changsha, China; 3. https://ror.org/04py1g812grid.412676.00000 0004 1799 0784Department of Oncology, The First Affiliated Hospital of Nanjing Medical University,Nanjing, China; 4. https://ror.org/059gcgy73grid.89957.3a0000 0000 9255 8984State Key Laboratory Cultivation Base of Biomarkers for Cancer Precision Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University,Nanjing, China; 5. https://ror.org/01413r497grid.440144.10000 0004 1803 8437Shandong Cancer Hospital,Jinan, China; 6. https://ror.org/0144s0951grid.417397.f0000 0004 1808 0985Zhejiang Cancer Hospital,Hangzhou, China; 7. https://ror.org/034haf133grid.430605.40000 0004 1758 4110The First Hospital of Jilin University,Changchun, China; 8. https://ror.org/04c8eg608grid.411971.b0000 0000 9558 1426The Second Hospital of Dalian Medical University,Dalian, China; 9. https://ror.org/007mrxy13grid.412901.f0000 0004 1770 1022West China Hospital of Sichuan University,Chengdu, China; 10. https://ror.org/0400g8r85grid.488530.20000 0004 1803 6191Sun Yat-sen University Cancer Center,Guangzhou, China; 11. https://ror.org/05d659s21grid.459742.90000 0004 1798 5889Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute,Shenyang, China; 12. https://ror.org/04wjghj95grid.412636.4The First Hospital of China Medical University,Shenyang, China; 13. https://ror.org/023rhb549grid.190737.b0000 0001 0154 0904Chongqing University Cancer Hospital,Chongqing, China; 14. https://ror.org/0152hn881grid.411918.40000 0004 1798 6427Tianjin Medical University Cancer Institute & Hospital,Tianjin, China; 15. https://ror.org/00v8g0168grid.452533.60000 0004 1763 3891Jiangxi Cancer Hospital,Nanchang, China; 16. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, Chengdu, China; 17. National Engineering Research Center of Targeted Biologics, Chengdu, China; 18. https://ror.org/02drdmm93grid.506261.60000 0001 0706 7839Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College,No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021 ChinaShow moreShow less
228
days
Pathogenic germline variants in BRCA1/2 are associated with a decreased number of hypomethylated rDNA copies
Authors
Sarah Kießling; Jana Durackova; Alina Michler; Alva B. C. Geisen; Natalia Santana Acevedo; Thomas HaafShow moreShow less
Affiliations
1. https://ror.org/00fbnyb24grid.8379.50000 0001 1958 8658Institute of Human Genetics, Julius Maximilians University,97074 Würzburg, Germany; 2. https://ror.org/01226dv09grid.411941.80000 0000 9194 7179Institute of Clinical Genetics and Genomic Medicine, University Clinics,97080 Würzburg, GermanyShow moreShow less
132
days
E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114
Authors
Hiroshi Ishiguro; Yasuo Miyoshi; Hiroyuki Yasojima; Junichiro Watanabe; Toshimi Takano; Akihiko Shimomura; Eriko Tokunaga; Toru Mukohara; Yasuto Naoi; Daiko Matsuoka; Shiori Okumura; Yohei Otake; Takuya Suzuki; Takao Takase; Taro Semba; Ziming Zhao; Kan YonemoriShow moreShow less
Affiliations
1. https://ror.org/03ftky336grid.412377.40000 0004 0372 168XBreast Oncology Service, Saitama Medical University International Medical Center,Hidaka, Japan; 2. https://ror.org/001yc7927grid.272264.70000 0000 9142 153XDepartment of Surgery, Division of Breast and Endocrine Surgery, Hyogo Medical University,Nishinomiya, Japan; 3. https://ror.org/03ntccx93grid.416698.4Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital,Osaka, Japan; 4. https://ror.org/01692sz90grid.258269.20000 0004 1762 2738Department of Breast Oncology, Juntendo University Graduate School of Medicine,Tokyo, Japan; 5. https://ror.org/03md8p445grid.486756.e0000 0004 0443 165XBreast Medical Oncology Department, The Cancer Institute Hospital of JFCR,Tokyo, Japan; 6. https://ror.org/00r9w3j27grid.45203.300000 0004 0489 0290Department of Breast and Medical Oncology, National Center for Global Health and Medicine,Tokyo, Japan; 7. https://ror.org/022296476grid.415613.4Department of Breast Oncology, NHO Kyushu Cancer Center,Fukuoka, Japan; 8. https://ror.org/03rm3gk43grid.497282.2Department of Medical Oncology, National Cancer Center Hospital East,Kashiwa, Japan; 9. https://ror.org/028vxwa22grid.272458.e0000 0001 0667 4960Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine,Kyoto, Japan; 10. https://ror.org/04vvh7p27grid.418765.90000 0004 1756 5390Japan and Asia Clinical Development Department, Oncology, Clinical Evidence Generation Fulfillment, Deep Human Biology Learning, Eisai Co., Ltd.,Tokyo, Japan; 11. https://ror.org/04vvh7p27grid.418765.90000 0004 1756 5390Clinical Research, Oncology, Clinical Evidence Generation Fulfillment, Deep Human Biology Learning, Eisai Co., Ltd.,Tokyo, Japan; 12. https://ror.org/04vvh7p27grid.418765.90000 0004 1756 5390Japan and Asia Clinical Data Science, Clinical Research, Deep Human Biology Learning, Eisai Co., Ltd.,Tokyo, Japan; 13. https://ror.org/04vvh7p27grid.418765.90000 0004 1756 5390Molecular Profiling Department, Discovery Concept Validation Function, Deep Human Biology Learning, Eisai Co., Ltd.,Ibaraki, Japan; 14. https://ror.org/0469x1750grid.418767.b0000 0004 0599 8842Human Biology Integration Foundation, Deep Human Biology Learning, Eisai Inc.,Nutley, NJ USA; 15. https://ror.org/0025ww868grid.272242.30000 0001 2168 5385Department of Medical Oncology, National Cancer Center Hospital,Tokyo, JapanShow moreShow less
157
days
Synergistic lethality of combination treatment with Trop2-directed antibody-drug conjugate sacituzumab govitecan and TRAIL agonists in triple negative breast cancer
Authors
Yonit A. Addissie; Yoshimi E. Greer; Jayakumar Nair; Stanley LipkowitzShow moreShow less
Affiliations
1. https://ror.org/040gcmg81grid.48336.3a0000 0004 1936 8075Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute,Bethesda, MD USAShow moreShow less
96
days
Variation in chemotherapy use across healthcare regions in Sweden and its impact on prognosis in women with HR+/HER2- early breast cancer
Authors
Balazs Acs; Xingrong Liu; Leo Gkekos; Emelie Karlsson; Anna L. V. Johansson; Per Karlsson; Anne Andersson; Antonios Valachis; Irma Fredriksson; Theodoros Foukakis; Johan HartmanShow moreShow less
Affiliations
1. https://ror.org/00m8d6786grid.24381.3c0000 0000 9241 5705Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital,Stockholm, Sweden; 2. https://ror.org/056d84691grid.4714.60000 0004 1937 0626Department of Oncology-Pathology, Karolinska Institutet,Stockholm, Sweden; 3. https://ror.org/056d84691grid.4714.60000 0004 1937 0626Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,Stockholm, Sweden; 4. https://ror.org/01tm6cn81grid.8761.80000 0000 9919 9582Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy and Sahlgrenska University Hospitial, University of Gothenburg,Gothenburg, Sweden; 5. https://ror.org/05kb8h459grid.12650.300000 0001 1034 3451Department of Diagnostics and Interventions, Oncology, Umeå University,Umeå, Sweden; 6. https://ror.org/05kytsw45grid.15895.300000 0001 0738 8966Department of Oncology, Faculty of Medicine and Health, Örebro University,Örebro, Sweden; 7. https://ror.org/056d84691grid.4714.60000 0004 1937 0626Department of Molecular Medicine and Surgery, Karolinska Institutet,Stockholm, Sweden; 8. https://ror.org/00m8d6786grid.24381.3c0000 0000 9241 5705Department of Breast-, Endocrine Tumors and Sarcoma, Karolinska Cancer Comprehensive Center, Karolinska University Hospital,Stockholm, Sweden; 9. Breast Center, Karolinska Comprehensive Cancer Center, Stockholm, Sweden; 10. https://ror.org/00m8d6786grid.24381.3c0000 0000 9241 5705MedTechLabs, Karolinska University Hospital, BioClinicum,NKS J5:20, Solnavägen, 30, 171 64 Solna, SwedenShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days